SynthesisFrontiers in endocrinology2026
Corneal endothelial changes in type 2 diabetes mellitus: a systematic review and meta-analysis with subgroup comparisons by diabetic retinopathy status and disease duration.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) affects multiple ocular structures, yet the extent of corneal endothelial alterations across different stages of diabetic retinopathy (DR) and disease duration remains unclear. This meta-analysis quantified corneal endothelial changes in T2DM across subgroups defined by DR status and diabetes duration. Methods: This systematic review adhered to PRISMA and MOOSE guidelines (PROSPERO: CRD420261473313). Five databases were searched from inception through July 15, 2026. Cross-sectional studies comparing endothelial cell density (ECD), coefficient of variation (CV), and percentage of hexagonal cells (HEX) in T2DM patients versus controls or between T2DM subgroups were included. Study quality was assessed using the AHRQ checklist. Effect sizes were calculated as Cohen's d using fixed-effect or random-effects models based on heterogeneity. Sensitivity analyses used the leave-one-out method; publication bias was assessed with funnel plots, Egger's test, and trim-and-fill analysis. Results: Twenty-two studies (5,878 eyes) were included. T2DM patients showed significantly lower ECD (d = -0.35, P < 0.001), higher CV (d = 0.25, P < 0.001), and lower HEX (d = -0.28, P < 0.001) versus controls. Eyes with DR had lower ECD (d = -0.22, P = 0.002), higher CV (d = 0.26, P = 0.005), and lower HEX (d = -0.23, P = 0.02) versus eyes without DR. No significant differences emerged between PDR and NPDR. Longer disease duration (≥10 years) was associated with lower ECD (d = -0.39, P = 0.04) and lower HEX (d = -0.18, P = 0.003). Sensitivity analyses showed that HEX (T2DM vs. controls), CV (PDR vs. NPDR), and CV (duration comparison) were not robust; trim-and-fill reversed the CV duration result. Conclusions: T2DM is associated with impaired corneal endothelial morphology, with greater changes in the presence of DR and longer duration. Several estimates were sensitive to individual studies or publication bias, warranting cautious interpretation. Preoperative endothelial assessment may be beneficial in diabetic patients, particularly those with DR or long disease duration. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261473313, identifier CRD420261473313.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.